Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by ...

People who talk in their sleep may be at greater risk of stroke, according to a study of 8,001 Chinese adults. The risk was ...

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.

There may be properties of anti-obesity medications that lead to reduced use. For example, naltrexone decreases cravings for alcohol and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...

Interoception research reveals how gut-brain communication via neural, hormonal, and microbial pathways regulates metabolism, ...

Known as GLP-1 receptor agonists, the new class of medicine mimic the action of a hormone called glucagon-like peptide 1, ...

The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19, researchers found.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...